#United States #San Diego #Class Action #MoonLake #MLTX

MoonLake Immunotherapeutics Investors Alert

On October 16, 2025, the law firm Robbins Geller Rudman & Dowd LLP announced a significant development regarding investors in MoonLake Immunotherapeutics (NASDAQ: MLTX). This announcement relates to a class action lawsuit titled Bridgewood v. MoonLake Immunotherapeutics, which is pending in the Southern District of New York. The lawsuit involves claims of securities fraud against the company and several of its high-ranking executives. Investors who have experienced substantial financial losses due to their investment in MoonLake commons are being called to step forward to potentially lead this class action lawsuit.

Background of the Lawsuit

MoonLake Immunotherapeutics is a biotechnology firm focused on developing treatments for inflammatory skin and joint diseases. The company's primary drug candidate, sonelokimab (SLK), was intended to serve as a viable treatment option for hidradenitis suppurativa (HS). However, for SLK to succeed commercially, it needed to demonstrate an efficacy comparable to or better than that of BIMZELX, a medication developed by Union Chimique Belge that is already FDA approved for the same condition.

The lawsuit alleges that during the class period, the defendants, including top executives at MoonLake, made numerous misrepresentations and false statements, as well as omissions of critical information. One of the key claims is that both SLK and BIMZELX target the same inflammatory cytokines, namely IL-17A and IL-17F. Additionally, the class action asserts that SLK’s unique Nanobody structure would not provide any significant clinical advantages over the traditional monoclonal structure used in BIMZELX.

Furthermore, the lawsuit mentions that although SLK was marketed as having superior tissue penetration, this claim did not translate into improved clinical outcomes. These misleading statements impacted the stock's value, leading to considerable losses for investors.

Price Drop and Investor Impact

A crucial moment occurred on September 28, 2025, when MoonLake announced the results from its Phase 3 VELA trial, which showed that SLK had failed to exhibit competitive efficacy in comparison to BIMZELX. Following this announcement, the value of MoonLake’s stock plummeted by almost 90%, causing profound financial distress to its investors. This drastic decline underlines the gravity of the allegations presented in the lawsuit and emphasizes the motivations of affected investors to seek recourse through legal channels.

Lead Plaintiff Process

Under the Private Securities Litigation Reform Act of 1995, investors who purchased or acquired MoonLake common stock during the specified class period have the right to apply for the position of lead plaintiff in the ongoing lawsuit. This lead plaintiff role is generally assumed by the individual with the greatest financial interest in the relief sought, as well as someone who can adequately represent the interests of the putative class.

It’s important to note that serving as the lead plaintiff is not a prerequisite for recovering losses in the case. All investors involved have the opportunity to benefit from any potential settlements or judgments obtained through the lawsuit, regardless of whether they take on this leadership role.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as one of the foremost law firms specializing in securities fraud and shareholder litigation. With a proven track record, the firm has consistently secured substantial monetary relief for investors over the years. In 2024 alone, they managed to recover over $2.5 billion for clients as part of various securities-related class actions, vastly outperforming other firms in the sector.

As of now, investors who wish to join the MoonLake class action lawsuit or require further information are encouraged to reach out to attorneys J.C. Sanchez or Jennifer N. Caringal from Robbins Geller via phone or email. The deadline for submitting lead plaintiff motions is set for December 15, 2025. This upcoming timeline is critical for investors looking to secure their position in the lawsuit and pursue justice for their financial losses.

For more comprehensive information on joining the lawsuit, individuals can visit the designated website of Robbins Geller.